179 related articles for article (PubMed ID: 23611569)
1. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study.
Edwards J; Sperry V; Adams MH; Gallipoli S; Thorn MD; Longstreth J; Boinpally R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):456-65. PubMed ID: 23611569
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
[TBL] [Abstract][Full Text] [Related]
3. Vilazodone (Viibryd)--a new antidepressant.
Med Lett Drugs Ther; 2011 Jul; 53(1368):53-4. PubMed ID: 21738107
[TBL] [Abstract][Full Text] [Related]
4. Vilazodone for the treatment of major depressive disorder.
Iranikhah M; Wensel TM; Thomason AR
Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
[TBL] [Abstract][Full Text] [Related]
5. Vilazodone: in major depressive disorder.
Frampton JE
CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
[TBL] [Abstract][Full Text] [Related]
6. Vilazodone: a novel antidepressant.
Choi E; Zmarlicka M; Ehret MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
[TBL] [Abstract][Full Text] [Related]
7. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
Jain R; Chen D; Edwards J; Mathews M
Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
[TBL] [Abstract][Full Text] [Related]
8. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
Guay DR
Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
[TBL] [Abstract][Full Text] [Related]
9. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
[TBL] [Abstract][Full Text] [Related]
10. Vilazodone for the treatment of depression.
Lindsey WT
Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Mathews M; Gommoll C; Chen D; Nunez R; Khan A
Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
14. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
15. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
Khan A
Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
[TBL] [Abstract][Full Text] [Related]
16. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
[TBL] [Abstract][Full Text] [Related]
17. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
19. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
20. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
